NABGEN, INC.
DURHAM, NC · Founded 2019 · CIK 0001916325 · Biotech · Private
Engineered protein (NG101) that blocks neutralizing antibodies against adeno-associated virus vectors for gene therapy
nabgen.com →- Grants
- $1.6M
- 3 awards
- Sector median: 1
- Raised
- $100K
- 1 Form D · Mar 2022
- 55 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Novel strategy to block AAV neutralizing anitbody activity | $300,000 | |
| Private capital raised | Form D · SEC | $100,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of an Effective Strategy to Block Nab Activity for AAV Brain Transduction | $269,640 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel strategy to block AAV neutralizing antibody activity | $993,865 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1224 | QENTOROS LLC | — | $605K |
| 1225 | Tetraphase Biosciences | — | — |
| 1226 | Savara Pharma | — | — |
| 1227 | NABGEN, INC. | — | $100K |
| 1228 | ERAD Therapeutics Inc. | — | $84K |
| 1229 | Gaingels LabGenius LLC | — | $64K |
| 1230 | EZRABIO INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Charles AskewDirector · Executive Officer · Promoter
- Chengwen LiDirector · Executive Officer
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.